4basebio (LON:4BB) Issues Earnings Results

4basebio (LON:4BB) issued its earnings results on Monday. The company reported GBX (0.57) EPS for the quarter, Digital Look Earnings reports.

4basebio Stock Down 0.5%

LON:4BB traded down GBX 2.70 during trading hours on Wednesday, reaching GBX 559.80. The company’s stock had a trading volume of 115 shares, compared to its average volume of 1,346. The company has a market cap of £86.69 million, a price-to-earnings ratio of -5.14 and a beta of 1.09. 4basebio has a one year low of GBX 420 and a one year high of GBX 820. The business’s 50-day moving average is GBX 512.25 and its 200-day moving average is GBX 510.12. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.

Analyst Ratings Changes

Separately, Royal Bank Of Canada lowered their price target on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating for the company in a research note on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of GBX 1,400.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.